Regulatory NewsBREAK: CMS Issues Final Negotiated Prices for Initial Price Applicability Year 2026
On Aug. 15, 2024, the Centers for Medicare & Medicaid Services (CMS) issued the Final Negotiated Prices for Initial Price Applicability Year 2026 under the Inflation Reduction Act (IRA). The drugs selected for this negotiation are Januvia, Fiasp, Farxiga, Enbrel, Jardiance, Stelara, Xarelto, Eliquis, Entresto, and Embruvica. Access the Regulatory NewsBREAK to learn more.
Related
On Dec. 12, 2024, the Centers for Medicare and Medicaid Services (CMS) issued a final rule titled, “Modifications of Health Insurance Portability and Accountability Act of 1996 (HIPAA) National Council for Prescription Drug Programs (NCPDP) Retail Pharmacy Standards; and Modification of the Medicaid Pharmacy Subrogation Standard” (Final Rule).
On December 4, 2024, the Centers for Medicare and Medicaid Services (CMS) announced that two drug manufacturers of gene therapies for sickle cell disease have entered into agreements to participate in the Cell and Gene Therapy Access Model (CGT Access Model).
On November 15, 2024, the Centers for Medicare & Medicaid Services (CMS) issued an update to the set of frequently asked questions (FAQs) related to the Medicare Prescription Payment Plan originally issued on October 1, 2024.
Featured News & Resources
See Full Calendar
Other Events
HBCU Travel Awards for AMCP25
Other Events
Mid-South AMCP Day of Education 2025
Other Events
Southwest AMCP Annual Day of Education 2025
Upcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
